BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 24911432)

  • 1. Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria.
    Clemens A; Noack H; Brueckmann M; Lip GY
    PLoS One; 2014; 9(6):e99276. PubMed ID: 24911432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis.
    Mainbourg S; Cucherat M; Provencher S; Bertoletti L; Nony P; Gueyffier F; Mismetti P; Grange C; Durieu I; Kilo R; Laporte S; Grenet G; Lega JC;
    Thromb Res; 2021 Jan; 197():24-32. PubMed ID: 33161284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
    López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
    BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
    [No Abstract]   [Full Text] [Related]  

  • 5. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
    Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J
    Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
    Weitz JI; Connolly SJ; Patel I; Salazar D; Rohatagi S; Mendell J; Kastrissios H; Jin J; Kunitada S
    Thromb Haemost; 2010 Sep; 104(3):633-41. PubMed ID: 20694273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of randomized controlled trials.
    Wang KL; Chiu CC; Su-Yin Tan D; Lin CY; Lai EY; Goto S; Giugliano RP; Chiang CE
    J Formos Med Assoc; 2017 Aug; 116(8):591-598. PubMed ID: 28645443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation.
    Ageno W; Beyer-Westendorf J; Rubboli A
    Expert Opin Pharmacother; 2017 Sep; 18(13):1325-1332. PubMed ID: 28786696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
    Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis.
    Huang WY; Singer DE; Wu YL; Chiang CE; Weng HH; Lee M; Ovbiagele B
    JAMA Neurol; 2018 Dec; 75(12):1511-1518. PubMed ID: 30105396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.
    Escobar C; Martí-Almor J; Pérez Cabeza A; Martínez-Zapata MJ
    Rev Esp Cardiol (Engl Ed); 2019 Apr; 72(4):305-316. PubMed ID: 29606361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twice- or once-daily dosing of direct oral anticoagulants and gastrointestinal bleeding in patient with atrial fibrillation.
    Ido T; Sasaki S; Sotomi Y; Hirata A; Makino N; Hayashi T; Sakata Y; Hirayama A; Higuchi Y
    Am Heart J Plus; 2022 Oct; 22():100203. PubMed ID: 38558905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.